HLB Life Science R&D Secures Two Major Government R&D Projects Worth $6.2 Million for AI Oncology and Medical Cannabis Development
核心洞察
HLB Life Science R&D (搜索) has been selected for two significant government-funded research projects totaling approximately $6.2 million, focusing on AI-driven oncology drug development and medical cannabis API localization.
The company will lead non-clinical trials for AI-identified cancer drug candidates in a three-year project worth $1.6 million, collaborating with Arontier (搜索) and K-MEDI hub through 2028.
In a separate $4.2 million initiative, HLB Life Science R&D (搜索) will develop high-purity cannabidiol APIs and conduct preclinical research to reduce Korea's complete dependence on imported medical cannabis compounds.
HLB Life Science R&D (搜索) has secured two major government research contracts worth a combined $6.2 million, positioning the company at the forefront of artificial intelligence-driven oncology drug development and medical cannabis API localization in South Korea.
AI-Powered Cancer Drug Development Initiative
The Ministry of Health and Welfare has selected HLB Life Science R&D (搜索) for a three-year artificial intelligence oncology drug development project with a total budget of 2.2 billion won ($1.6 million). The initiative, running through 2028, aims to leverage AI technology to identify cancer drug candidates from initial discovery through lead compound stages.
HLB Life Science R&D (搜索) will serve as a joint research institution alongside Arontier (搜索), which leads the consortium, and the Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI hub). The company's specific responsibility involves conducting non-clinical trials to validate AI-identified drug candidates through efficacy evaluations and animal testing.
"This project aims to enhance the development potential of oncology drug candidates by combining AI-based drug discovery technologies with non-clinical validation capabilities," stated an HLB Life Science R&D (搜索) representative. The company plans to accumulate foundational data on efficacy and safety profiles of candidates identified through the AI platform, potentially increasing their development potential for future clinical advancement.
Medical Cannabis API Localization Project
In a separate initiative, HLB Life Science R&D (搜索) has joined a consortium selected for the "Agricultural Bio-resource-based National Essential Medicine Raw Material Supply Chain Response Technology Development Project," funded by the Ministry of Agriculture, Food and Rural Affairs. The project carries a total budget of approximately 5.7 billion won ($4.2 million).
The initiative focuses on establishing an advanced production platform for cannabidiol (CBD) active pharmaceutical ingredients and developing cultivation technologies to secure stable raw material supplies. Currently, South Korea relies entirely on imports for high-purity CBD APIs, creating a strategic vulnerability in the medical cannabis supply chain.
HLB Life Science R&D (搜索) will utilize approximately 1.7 billion won of the project funding to conduct core research activities, including discovering preclinical indications based on hemp-derived CBD, establishing chemistry, manufacturing and controls (CMC) protocols, and preparing investigational new drug (IND) applications.
Strategic Implications for Drug Development
CBD, a non-psychoactive compound extracted from cannabis, has attracted significant attention for its potential therapeutic applications in anticancer treatment, anti-inflammatory therapy, and skin disease treatment. The consortium includes HLB Life Science R&D (搜索), Neocan Bio (搜索), Apac (搜索), Topolab (搜索), Dongguk University, Gyeongguk National University, and the Gyeongbuk Institute for Bioindustry.
The company expects to accumulate comprehensive R&D experience spanning the full development cycle from preclinical research through CMC to IND preparation stages. This experience is anticipated to strengthen HLB Life Science R&D (搜索)'s pipeline expansion capabilities and technology commercialization foundation.
"This project selection is a meaningful achievement that once again demonstrates HLB Life Science R&D (搜索)'s research capabilities and technological competitiveness," said CEO Kim Yeon-tae. "We will work closely with consortium partners to build a foundation for localizing high-purity CBD APIs and continue to expand related R&D efforts."
Both projects represent significant strategic investments in emerging therapeutic areas, positioning HLB Life Science R&D (搜索) to leverage cutting-edge technologies while addressing critical supply chain vulnerabilities in South Korea's pharmaceutical sector.